☆ 4.7 Article

First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part

CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort

Norikazu Masuda et al.

Summary: This study evaluated the safety and efficacy of a liposomal formulation of eribulin, E7389-LF, in breast cancer patients. The results showed that E7389-LF had favorable antitumor activity, particularly in hormone receptor-positive breast cancer patients. Prophylactic pegfilgrastim may be considered for reducing the risk of neutropenia and febrile neutropenia.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Review Cell Biology

Transforming Growth Factor-β: An Agent of Change in the Tumor Microenvironment

Christina H. Stuelten et al.

Summary: TGF-beta plays a dual role in tumors, acting as an inhibitor of early-stage tumorigenesis while promoting late-stage tumor progression and metastasis. Through its ability to alter cell differentiation, TGF-beta induces transitions of various cell types, contributing to the progression of epithelial tumors.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Cell Biology

TGF-β Signaling and Resistance to Cancer Therapy

Maoduo Zhang et al.

Summary: The TGF-beta pathway in cancer has dual roles and is considered a potential new avenue for cancer therapy, but its functions and mechanisms of action require further investigation.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Oncology

Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy

Hans Raskov et al.

Summary: Understanding the tumor microenvironment is crucial for innovating new therapeutic approaches in cancer treatment, especially the cell-cell communication within the TME. Cancer-associated fibroblasts (CAF) and tumor-associated macrophages (TAM) are major cell populations in solid tumors with potential as therapeutic targets. Further research and innovation are needed to fully comprehend the roles of CAF and TAM in cancer and improve targeted treatment strategies.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

Ksenia M. Yegodayev et al.

CANCERS (2020)

Add to Collection

Article Multidisciplinary Sciences

A selective inference approach for false discovery rate control using multiomics covariates yields insights into disease risk

Ronald Yurko et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Medicine, Research & Experimental

Radio resistance in breast cancer cells is mediated through TGF-β signalling, hybrid epithelial-mesenchymal phenotype and cancer stem cells

Poonam Yadav et al.

BIOMEDICINE & PHARMACOTHERAPY (2019)

Add to Collection

Article Oncology

Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5

Ziqian Li et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

Add to Collection

Article Oncology

GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway

Yan-Liang Li et al.

ONCOTARGET (2017)

Add to Collection

Article Medicine, Research & Experimental

TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer

Junlong Zhuang et al.

THERANOSTICS (2017)

Add to Collection

Article Oncology

Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models

Ken Ito et al.

CANCER SCIENCE (2017)

Add to Collection

Article Oncology

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab

Shigeto Ueda et al.

BRITISH JOURNAL OF CANCER (2016)

Add to Collection

Article Biochemistry & Molecular Biology

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

Naoki Oshimori et al.

CELL (2015)

Add to Collection

Article Oncology

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Yasuhiro Funahashi et al.

CANCER SCIENCE (2014)

Add to Collection

Article Medicine, Research & Experimental

A modified toxicity probability interval method for dose-finding trials

Yuan Ji et al.

CLINICAL TRIALS (2010)

Add to Collection

Article Chemistry, Medicinal

Macrocyclic ketone analogues of halichondrin B

WJ Zheng et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.